Physician profile
Vaughn Dobalian
NPI 1245260199
$6,862.08
in general payments reported to CMS, 2019-2025
22 companies · $594 in 2025
The $594 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,737 · 2020: $1,140 · 2021: $1,444 · 2022: $860 · 2023: $366 · 2024: $721 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.62 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,497.55 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,156.38 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $1,079.38 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $618.81 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $383.53 | 2019-2023 | Steglatro, Steglujan |
| Novartis Pharmaceuticals Corporation | $187.86 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.74 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $141.36 | 2019 | |
| Abiomed | $130.50 | 2025 | |
| Vanda Pharmaceuticals INC. | $123.95 | 2025 | Fanapt |
| Boston Scientific Corporation | $101.52 | 2022 | |
| Orexo US, INC. | $62.15 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $33.42 | 2022 | |
| Allergan, INC. | $27.11 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.59 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $20.18 | 2020 | |
| Indivior INC. | $18.41 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.39 | 2021 | |
| Melinta Therapeutics, LLC | $15.38 | 2019 | |
| Amgen INC. | $14.61 | 2024 | Otezla, Repatha |
| Pfizer INC. | $14.15 | 2019 | |
| Amarin Pharma, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaughn Dobalian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.